Pharmaceutical Technology
OCTOBER 24, 2023
Pear Therapeutics was a pioneer in developing DTx for neurological conditions traditionally treated by evidence-based behavioural or psychological management strategies.
Bio Pharma Dive
OCTOBER 24, 2023
The money will be spread across three investment funds and comes at a time when investment into biotech remains shakier than in years past.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
OCTOBER 24, 2023
SpeechDx will contain recorded voice samples and other data, which will be used to develop algorithms for creating new speech biomarkers.
Bio Pharma Dive
OCTOBER 24, 2023
The startup is taking aim at an inflammation-linked protein known as TSLP, which is the target of an approved asthma medicine.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
OCTOBER 24, 2023
The candidate recently went through a Phase II trial, with results to be presented in mid-November.
Bio Pharma Dive
OCTOBER 24, 2023
Rampart Biosciences closed a Series A round that will fund its goal to develop more potent DNA-based medicines that avoid immune responses.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 24, 2023
If the idea of driving down a winding road makes you feel queasy, spare a thought for the mice employed in a new study, which sought to pinpoint the brain cells responsible for motion sickness.
Bio Pharma Dive
OCTOBER 24, 2023
Mixed survival data from a study of Pluvicto in earlier prostate cancer sparked the slower regulatory timeline.
AuroBlog - Aurous Healthcare Clinical Trials blog
OCTOBER 24, 2023
The National Accreditation Board for Hospitals and Healthcare Providers (NABH) has released the first edition of NABH Certification standards for stroke care centres. It has urged all the centres across the country to apply for accreditation depending on the self-assessment of the standards.
Pharmaceutical Technology
OCTOBER 24, 2023
At the ongoing CpHI Europe meeting, experts outline the key elements that will be expected in future pharma partnerships.
Pharma Times
OCTOBER 24, 2023
Malaria was responsible for over 600,000 worldwide deaths in 2021 - News - PharmaTimes
Pharmaceutical Technology
OCTOBER 24, 2023
The award will fund the development of the company’s automated, microfluidic cell and gene therapy manufacturing platform.
Pharma Times
OCTOBER 24, 2023
The funding will allow several projects to support the health of working people - News - PharmaTimes
Fierce Pharma
OCTOBER 24, 2023
In the biopharma industry, post-merger layoffs are often a question of when and how many. | In the biopharma industry, post-merger layoffs are often a question of when and how many. In the case of Amgen’s $27.8 billion buyout of Horizon, they came quickly. Around 350 former Horizon employees are being told this week that their positions will be eliminated.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
OCTOBER 24, 2023
Amidst a changing, complex Covid-19 marketplace, HDT-Bio looks towards harnessing multivalence for its Covid-19 candidate, HDT-301.
Worldwide Clinical Trials
OCTOBER 24, 2023
In the US, a rare disease is one with 200,000 or fewer patients. Rare diseases exist in every therapeutic area and are often the more complex indications of each therapeutic area. While this is a small number of people in each rare disease patient community, the significant and continued growth of rare disease drug development is unsurprising given that there are over 10,000 rare diseases , with more being discovered every year.
Pharmaceutical Technology
OCTOBER 24, 2023
Sponsors are being urged to compensate participants in oncological clinical trials, as well as make in-person visits to contract research organisations to keep exploratory studies from slowing down.
BioSpace
OCTOBER 24, 2023
In its most recent round of layoffs this year, the California-based biopharma company is letting go of 350 former Horizon Therapeutics staff whose roles overlap with existing positions at Amgen.
Pharmaceutical Technology
OCTOBER 24, 2023
AstraZeneca will pay $75m to Daiichi Sankyo as a milestone payment following the latest EU approval to treat NSCLC patients with a HER2 mutation.
Fierce Pharma
OCTOBER 24, 2023
At this year’s congress of the European Society for Medical Oncology (ESMO), Merck & Co. unleashed a flurry of studies showing Keytruda’s power across multiple tumor types. | Across four separate studies, Merck’s PD-1 juggernaut Keytruda—in combination with other cancer meds—charted complete and partial wins in cervical cancer, early breast cancer and stomach cancer.
Pharmaceutical Technology
OCTOBER 24, 2023
A panel discussion at a Copenhagen conference saw representatives from sponsor organisations sharing their hopes for CROs to take ownership when trials go wrong.
pharmaphorum
OCTOBER 24, 2023
Creating behavioural change through incremental, small steps Mike.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Technology
OCTOBER 24, 2023
Health Canada has granted approval for Sumitomo Pharma Canada’s Orgovyx (relugolix) to treat advanced prostate cancer in men.
Fierce Pharma
OCTOBER 24, 2023
On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. | On the market for two decades, AstraZeneca’s nasal spray flu vaccine, FluMist, may become available for self-administration as soon as next year. The FDA has accepted AZ’s supplemental biologics license application (sBLA) for self-administered FluMist Qudrivalent.
Pharmaceutical Technology
OCTOBER 24, 2023
Samsung Biologics has entered into a collaboration with Kurma Partners to develop biologics for Kurma's portfolio companies.
pharmaphorum
OCTOBER 24, 2023
ESMO: Survival data mars Pluvicto prostate cancer trial Phil.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
OCTOBER 24, 2023
The Indonesian Ministry of Food and Drug Safety approved Genexine and KGbio's Efepoetin alfa for chronic kidney disease-induced anaemia.
pharmaphorum
OCTOBER 24, 2023
ESMO: Can BioNTech’s revved-up CAR-T hit solid tumours? Phil.
Pharmaceutical Technology
OCTOBER 24, 2023
INVO Bioscience has signed an agreement to acquire NAYA Biosciences to establish a publicly traded life science company.
Fierce Pharma
OCTOBER 24, 2023
Novartis entered a new era after spinning off Sandoz earlier in October. | Novartis entered a new era after spinning off Sandoz earlier in October. As the pure-play innovative medicines company reports strong growth from the business it’s now built on, one product faces a delay.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
182 
Let's personalize your content